The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percutaneous coronary intervention

Journal of Thoracic Disease

Volumn 5, Issue 3, 2013, Pages 258-264

  Soylu, Korhan ^a   Yuksel, Serkan ^a   Gulel, Okan ^a   Erbay, Ali Riza ^a   Meric, Murat ^a   Zengin, Halit ^a   Museyibov, Muhtar ^a   Yasar, Erdogan ^a   Demircan, Sabri ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Acute ST segment elevation myocardial infarction (acute STEMI); Inflammation; Neutrophil lymphocyte ratio (N L ratio)

Indexed keywords

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY REPERFUSION; CORRELATIONAL STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOLYSIS IN MYOCARDIAL INFARCTION;

EID: 84881500017     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.05.13     Document Type: Article

References (33)

1. Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Korkmaz L, Kul S, Korkmaz AA, et al. Increased leucocyte count could predict coronary artery calcification in patients free of clinically apparent cardiovascular disease. Turk Kardiyol Dern Ars 2012;40:223-8.
3. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.
4. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991;83:836-44.
5. Shen XH, Chen Q, Shi Y, et al. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl) 2010;123:3438-43.
6. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102:653-7.
7. Lee CH, Wong HB, Tan HC, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol 2005;18:261-6.
8. Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on sixmonth mortality. Am J Cardiol 2007;99:442-5.
9. Romano M, Buffoli F, Tomasi L, et al. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. J Cardiovasc Med (Hagerstown) 2008;9:59-63.
10. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of noreflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010;55:2383-9.
11. Charron T, Jaffe R, Segev A, et al. Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thromb Res 2010;126:50-5.
12. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012;110:621-7.
13. Oduncu V, Tanalp AC, Erkol A, et al. Impact of chronic pre-treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty. Am J Cardiol 2011;107:179-85.
14. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
15. Gibson CM, Schömig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004;109:3096-105.
16. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
17. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-30.
18. Topsakal R, Kaya MG, Karakaya E, et al. Relationship between no-reflow phenomenon and serotonin levels in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous intervention. Anadolu Kardiyol Derg 2010;10:253-9.
19. Esen AM, Acar G, Esen O, et al. The prognostic value of combined fractional flow reserve and TIMI frame count measurements in patients with stable angina pectoris and acute coronary syndrome. J Interv Cardiol 2010;23:421-8.
20. De Luca G, Suryapranata H, de Boer MJ, et al. For the Ongoing Tirofiban In Myocardial Infarction Evaluation (On-TIME) study group. Combination of electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty. Int J Cardiol 2007;117:232-7.
21. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 2011;16:244-50.
22. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101:359-72.
23. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-508.
24. Sahin DY, Elbasan Z, Gür M, et al. Neutrophil to Lymphocyte Ratio Is Associated With the Severity of Coronary Artery Disease in Patients With ST-Segment Elevation Myocardial Infarction. Angiology 2012. [Epub ahead of print].
25. Zazula AD, Précoma-Neto D, Gomes AM, et al. An assessment of neutrophils/lymphocytes ratio in patients suspected of acute coronary syndrome. Arq Bras Cardiol 2008;90:31-6.
26. Núñez J, Núñez E, Bodí V, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008;101:747-52.
27. Muhmmed Suliman MA, Bahnacy Juma AA, Ali Almadhani AA, et al. Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome. Arch Med Res 2010;41:618-22.
28. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111:636-42.
29. Han YC, Yang TH, Kim DI, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Korean Circ J 2013;43:93-9.
30. Amanvermez R, Acar E, Günay M, et al. Hsp 70, hsCRP and oxidative stress in patients with acute coronary syndromes. Bosn J Basic Med Sci 2012;12:102-7.
31. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
32. Ndrepepa G, Tiroch K, Keta D, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010;3:27-33.
33. Niccoli G, Lanza GA, Spaziani C, et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007;117:306-11.